Cost analysis of chronic obstructive pulmonary disease (COPD): a systematic review

Celia Gutiérrez Villegas, María Paz-Zulueta, Manuel Herrero-Montes, Paula Parás-Bravo, María Madrazo Pérez, Celia Gutiérrez Villegas, María Paz-Zulueta, Manuel Herrero-Montes, Paula Parás-Bravo, María Madrazo Pérez

Abstract

Background: Chronic Obstructive Pulmonary Disease (COPD) is a treatable disease with a high prevalence, and high morbidity associated with significant socioeconomic costs.

Objective: To carry out a systematic review of the literature to analyze the main cost studies associated with COPD, in order to determine the main factors that influence the costs of the disease.

Methods: Searches were conducted in PubMed, SCOPUS and Web of Science databases for cost studies on COPD published in English, between the years 2015 and 2020. The search terms were "COPD" OR "pulmonary disease, chronic obstructive", "cost*" OR "cost of illness", "economic impact" AND "burden of disease". The inclusion criteria included the identification of reported cost of the disease, economic burden, medical care expenses or use resources for COPD, the methodology used, data sources, and variables studied.

Results: 18 publications were analyzed: 17 included direct health costs, 6 included direct non-medical costs, 12 analyzed indirect costs and two reported intangible costs. Most of the studies reported data for developed and European countries, with direct costs being the most studied. Trends were observed in multiple studies of direct and healthcare costs for European countries measured by patient and year, where the higher costs were associated with more severe COPD and a frequent history of exacerbations. The highest costs reported corresponded to hospitalizations and the associated pharmacological treatment. The importance of the loss of productivity and premature retirement within the profile of the COPD patient was also highlighted as the main generator of indirect costs of the disease.

Conclusion: COPD generates substantial costs for the health system, mainly related to moderate to severe stages and the exacerbations and complications entailed. It is important to strengthen health systems with monitoring, evaluation and health education models that allow these patients to remain stable to avoid decompensation and subsequent hospitalizations.

Keywords: Chronic obstructive; Cost of illness; Health care costs; Investments; Pulmonary disease; Systematic review.

Conflict of interest statement

The authors declare no conflict of interest.

© 2021. The Author(s).

Figures

Fig. 1
Fig. 1
Flow diagram of literature search

References

    1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary Disease [Monograph on the Internet]. USA: Global Initiative for Chronic Obstructive Lung Disease; 2020 [Accessed Dec 15, 2020]. Available at :
    1. Grupo de trabajo de GesEPOC. Guía de Práctica Clínica para el Diagnóstico y Tratamiento de Pacientes con Enfermedad Pulmonar Obstructiva Crónica (EPOC) – Guía española de la EPOC (GesEPOC). Versión 2017. Arch Bronconeumol [Internet] 2017 junio [citado 20 diciembre 2020]; 53(1): 2–64. 10.1016/S0300-2896(12)70035-2.
    1. González Del Castillo J, Candel FJ, de la Fuente Federico Gordo J et al. Manejo integral del paciente con exacerbación aguda de la enfermedad pulmonar. Rev Esq Quimioter [Internet] 2018 October [Accessed 20 Dec 2020]; 31(5):461–84. Available at:
    1. Cerezo-Lajas A, Rodríguez-Jimeno E, Gallo-González V et al. Mortalidad y factores asociados al reingreso en pacientes dados de alta tras una exacerbación aguda de EPOC. Rev Patol Respit [Internet] 2018 September [Accessed 22 Dec 2020]; 21(3):78–85. Available at:
    1. Urrútia G, Bonfill X. Declaración PRISMA: una propuesta para mejorar la publicación de revisiones sistemáticas y metaanálisis. Med Clin (Barc) [Internet] 2010;135(11):507–511. doi: 10.1016/j.medcli.2010.01.015.
    1. Foo J, Landis SH, Maskell J, et al. Continuing to Confront COPD International Patient Survey: Economic Impact of COPD in 12 Countries. PloS One [Internet] 2016;11(4):e0152618. doi: 10.1371/journal.pone.0152618.
    1. Wacker ME, Jorres RA, Schulz H, et al. Direct and indirect costs of COPD and its comorbidities: Results from the German COSYCONET study. Respir Med [Internet] 2016;111:39–46. doi: 10.1016/j.rmed.2015.12.001.
    1. Chen W, FitzGerald JM, Sin DD, et al. Excess economic burden of comorbidities in COPD: a 15 year population-based study. Eur Respir J [Internet] 2017;50:1700393. doi: 10.1183/13993003.00393-2017.
    1. Tachkov K, Kamusheva M, Pencheva V, Mitov K. Evaluation of the economic and social burdne of Chronic obstructive pulmonary disease (COPD) Biotechnol Biotechnol Equip [Internet] 2017;31(4):855–861. doi: 10.1080/13102818.2017.1335616.
    1. Wacker ME, Kitzing K, Jorres RA, et al. The contribution of symptoms and comorbidities to the economic impact of COPD: an analysis of the German COSYCONET cohot. Int J Chron Obstruct Pulmon Dis [Internet] 2017;12:3437–3448. doi: 10.2147/COPD.S141852.
    1. Quang Vo T, Ngoc Phung TC, Quoc Vu T, et al. Cost trend analysis of Chronic obstructive pulmonary disease among Vietnamese patients: Findings from two provincial facilities 2015-2017. J Clin Diagn Res [Internet] 2018;12(6):LC92–LC98. doi: 10.7860/JCDR/2018/36668.11715.
    1. Lakiang T, Nair NS, Ramaswamy A, et al. Economic impact of Chronic obstructive pulmonary disease: A cross-sectional study at teaching hospital in South India. J Family Med Prim Care [Internet] 2018;7:1002–1006. doi: 10.4103/jfmpc.jfmpc_75_16.
    1. Lisspers K, Larsson K, Johansson G, et al. Economic burden of COPD in a Swedish cohort: the ARCTIC study. Int J Chron Obstruct Pulmon Dis [Internet] 2018;13:275–285. doi: 10.2147/COPD.S149633.
    1. Merino M, Villoro R, Hidalgo-Vega A, et al. Social economic costs of COPD in Extremadura (Spain): an observational study. Int J Chron Obstruct Pulmon Dis [Internet] 2018;13:2501–2514. doi: 10.2147/COPD.S167357.
    1. Patel JG, Coutinho AD, Lunacsek OE, et al. COPD affects worker productivity and health care costs. Int J Chron Obstruct Pulmon Dis [Internet] 2018;13:2301–2311. doi: 10.2147/COPD.S163795.
    1. Stafyla E, Geitona M, Kerenidi T, et al. The annual direct costs of stable COPD in Greece. Int J Chron Obstruct Pulmon Dis [Internet] 2018;13:309–315. doi: 10.2147/COPD.S148051.
    1. Zhu B, Wang Y, Ming J, et al. Disease burden of COPD in China: a systematic review. Int J Chron Obstruct Pulmon Dis [Internet] 2018;13:1353–1364. doi: 10.2147/COPD.S161555.
    1. Changhwan Kim MD, Younhee Kim PD, Dong-Wook Yang PD, et al. Direct and indirect costs of Chronic obstructive pulmonary disease in Korea. Tuberc Respir Dis (Seoul) [Internet] 2019;82(1):27–34. doi: 10.4046/trd.2018.0035.
    1. Rehman AU, Admad Hassali MA, Ayaz Muhammad S, et al. The economic burden of Chronic obstructive pulmonary disease (COPD) in the USA, Europe, and Asia: results from a systematic review of the literature. Expert Rev Pharmacoecon Outcomes Res [Internet] 2019;18:1–12. doi: 10.1080/14737167.2020.1678385.
    1. Viinanen A, Lassenius MI, Toppila I, et al. The burden of Chronic obstructive pulmonary disease (COPD) in Finland: Impact of disease severity and eosinophil count on healthcare resource utilization. Int J Chron Obstruct Pulmon Dis [Internet] 2019;14:2409–2421. doi: 10.2147/COPD.S222581.
    1. Woo L, Smith HE, Sullivan SD. The economic burden of Chronic obstructive pulmonary disease in the Asia-Pacific Region: A systematic review. Value Health Reg Issues [Internet] 2019;18:121–131. doi: 10.1016/j.vhri.2019.02.002.
    1. Iheanacho I, Zhang S, King D, et al. Economic burden of Chronic obstructive pulmonary disease (COPD): A systematic literature review. Int J Chron Obstruct Pulmon Dis [Internet] 2020;15:439–460. doi: 10.2147/COPD.S234942.
    1. Rehman AU, Ahmad Hassali MA, Ayaz Muhammad S, et al. The economic burden of Chronic obstructive pulmonary disease (COPD) in Europe: results from a systematic review of the literature. Eur J Health Econ [Internet] 2020;21(2):181–194. doi: 10.1007/s10198-019-01119-1.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren